Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? - Université de Lille Accéder directement au contenu
Article Dans Une Revue Current Oncology Année : 2023

Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?

Résumé

This single-center study aimed to retrospectively evaluate the survival outcomes of patients with FIGO stage I clear cell and serous uterine carcinoma according to the type of adjuvant treatment received. The data were collected between 2003 and 2020 and only patients with stage I clear cell or serous uterine carcinoma treated with primary surgery were included. These were classified into three groups: No treatment or brachytherapy only (G1), radiotherapy +/− brachytherapy (G2), chemotherapy +/− radiotherapy +/− brachytherapy (G3). In total, we included 52 patients: 18 patients in G1, 16 in G2, and 18 in G3. Patients in the G3 group presented with poorer prognostic factors: 83.3% had serous histology, 27.8% LVSI, and 27.8% were FIGO stage IB. Patients treated with adjuvant radiotherapy showed an improved 5-year overall survival (OS) (p = 0.02) and a trend towards an enhanced 5-year progression-free survival (PFS) (p = 0.056). In contrast, OS (p = 0.97) and PFS (p = 0.84) in the chemotherapy group with poorer prognostic factors, were similar with increased toxicity (83.3%). Radiotherapy is associated with improved 5-year OS and tends to improve 5-year PFS in women with stage I clear cell and serous uterine carcinoma. Additional chemotherapy should be cautiously considered in serous carcinoma cases presenting poor histological prognostic factors.
Fichier principal
Vignette du fichier
curroncol-30-00090-v3.pdf (1.72 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Dates et versions

hal-04415318 , version 1 (24-01-2024)

Licence

Paternité

Identifiants

Citer

M. Lefebvre, M. Duchatelet, H. E. Hajj, A. Courrèges, J. Wallet, et al.. Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?. Current Oncology, 2023, Current Oncology, 30, pp.1174-1185. ⟨10.3390/curroncol30010090⟩. ⟨hal-04415318⟩
10 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More